CNTX · Context Therapeutics Inc.
Context Therapeutics Inc (CNTX)
What's happening
- CNTX is down 6.81% today, trading at $0.23. — Live quote
- It's trading within 3% of its 52-week low ($0.22). (Finnhub fundamentals)
- Volume today (33,429) is well below its 3-month average of 2,376,470. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.15 actual vs. $-0.09 estimated (-59.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $53.5M | $253.7M | $92.1M | $67.7M | $56.7M |
| P/E | -1.28 | -7.98 | -2.27 | -2.04 | -2.03 |
| Price/Book | 1.40 | 4.86 | 1.26 | 0.82 | 0.62 |
| EV/EBITDA | -0.23 | -5.65 | -0.34 | — | — |
| ROE | -109.40% | -60.88% | -55.43% | -40.12% | -30.73% |
| ROA | -90.52% | -53.99% | -51.19% | -38.00% | -30.08% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-08-05; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -81.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CNTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$15.0M | -$9.3M | -$10.6M | -$9.8M | -$5.5M | -$18.7M | -$3.1M | -$3.8M |
| Net income | -$14.6M | -$8.7M | -$9.7M | -$8.8M | -$4.6M | -$17.5M | -$2.3M | -$3.7M |
| EPS (diluted) | $-0.15 | $-0.09 | $-0.10 | $-0.09 | $-0.05 | $-0.22 | $-0.04 | $-0.23 |
| EPS (basic) | $-0.15 | $-0.09 | $-0.10 | $-0.09 | $-0.05 | $-0.22 | $-0.04 | $-0.23 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $46.1M | $58.9M | $68.5M | $79.2M | $87.2M | $93.0M | $98.1M | $86.3M |
| Total liabilities | $8.0M | $6.7M | $8.0M | $6.1M | $4.6M | $2.0M | $2.9M | $2.5M |
| Stockholders' equity | $38.2M | $52.2M | $60.5M | $73.2M | $82.5M | $91.0M | $95.3M | $83.9M |
| Total current assets | $45.8M | $58.5M | $68.4M | $79.1M | $86.9M | $92.7M | $97.9M | $86.1M |
| Total current liabilities | $7.9M | $6.5M | $8.0M | $6.0M | $4.6M | $1.9M | $2.7M | $2.3M |
| Cash & equivalents | $43.0M | $54.5M | $66.0M | $76.9M | $83.5M | $89.4M | $94.4M | $84.8M |
| Property, plant & equipment | $74.1K | $62.2K | $29.7K | $33.7K | $37.8K | $41.9K | $12.0K | $14.9K |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $3.3M | $2.5M | $2.5M | $2.7M | $2.4M | $1.0M | $1.5M | $1.0M |
| Accrued liabilities | $4.4M | $3.9M | $5.4M | $3.2M | $2.0M | $787.8K | $1.2M | $1.2M |
| Common stock & paid-in capital | $91.9K | $91.9K | $91.9K | $91.9K | $89.7K | $89.7K | $89.7K | $75.0K |
| Retained earnings | -$154.1M | -$139.6M | -$130.9M | -$117.9M | -$108.2M | -$99.4M | -$94.8M | -$91.4M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.0M | -$11.4M | -$8.9M | -$6.6M | -$5.8M | -$5.0M | -$4.9M | -$1.9M |
| Investing cash flow | -$4.5M | -$37.3K | -$2.0M | $0 | $0 | -$33.9K | $0 | -$14.8M |
| Financing cash flow | $0 | $0 | $0 | $0 | $0 | -$15.3K | $14.5M | -$44.6K |
| Free cash flow | -$7.0M | -$11.5M | -$8.9M | -$6.6M | -$5.8M | -$5.1M | -$4.9M | -$1.9M |
| Capital expenditures | $18.5K | $37.3K | $0 | $0 | $0 | $33.9K | $0 | $7.3K |
| Depreciation & amortization | $6.6K | $4.7K | $4.1K | $4.1K | $4.1K | $4.1K | $2.9K | $2.8K |
| Share-based compensation | $528.1K | $409.2K | $325.2K | $323.1K | $389.1K | $293.7K | $231.8K | $213.0K |
| Change in accounts payable | $822.5K | -$67.2K | -$188.0K | $325.0K | $1.4M | -$435.6K | $408.3K | $461.8K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$39.7M | -$29.9M | -$25.1M | -$15.4M | -$10.5M |
| Net income | -$36.1M | -$26.7M | -$24.0M | -$14.8M | -$10.5M |
| EPS (diluted) | $-0.38 | $-0.46 | $-1.50 | $-0.93 | $-3.69 |
| EPS (basic) | $-0.38 | $-0.46 | $-1.50 | $-0.93 | $-3.69 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $68.5M | $98.1M | $16.1M | $38.0M | $51.3M |
| Total liabilities | $8.0M | $2.9M | $4.2M | $3.2M | $3.0M |
| Stockholders' equity | $60.5M | $95.3M | $11.9M | $34.8M | $48.3M |
| Total current assets | $68.4M | $97.9M | $16.0M | $37.9M | $51.3M |
| Total current liabilities | $8.0M | $2.7M | $4.2M | $3.2M | $3.0M |
| Cash & equivalents | $66.0M | $94.4M | $14.4M | $35.5M | $49.6M |
| Property, plant & equipment | $29.7K | $12.0K | $15.5K | $27.6K | $0 |
| Other non-current assets | — | — | $0 | $32.8K | $0 |
| Accounts payable | $2.5M | $1.5M | $2.4M | $936.3K | $1.8M |
| Accrued liabilities | $5.4M | $1.2M | $1.8M | $2.2M | $1.2M |
| Common stock & paid-in capital | $91.9K | $89.7K | $16.0K | $16.0K | $16.0K |
| Retained earnings | -$130.9M | -$94.8M | -$68.1M | -$44.1M | -$29.3M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$26.4M | -$14.6M | -$21.0M | -$13.5M | -$8.8M |
| Investing cash flow | -$2.0M | -$14.8M | $0 | -$536.8K | -$250.0K |
| Financing cash flow | -$15.3K | $109.3M | $0 | -$102.1K | $58.4M |
| Free cash flow | -$26.4M | -$14.6M | -$21.0M | -$13.6M | -$8.8M |
| Capital expenditures | $33.9K | $7.3K | $0 | $36.8K | $0 |
| Depreciation & amortization | $16.3K | $10.9K | $12.0K | $9.3K | $0 |
| Share-based compensation | $1.3M | $841.9K | $1.1M | $976.4K | $511.1K |
| Change in accounts payable | $1.1M | -$946.1K | $1.4M | -$787.9K | -$866.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CNTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-06 to 2025-06-09
Recent transactions
- Most recent: Lehr Martin A. (Chief Executive Officer) — Open market purchase of 100,000 shares on 2025-06-09.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Lehr Martin A. | Chief Executive Officer | Open market purchase | 2025-06-09 | 100,000 |
| Levit Alex C. | Chief Legal Officer, Corp. Sec | Open market purchase | 2025-06-06 | 20,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer | Open market purchase | 2025-06-06 | 40,010 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-06-09 | Lehr Martin A. | Chief Executive Officer | Open market purchase | 100,000 | $0.70 |
| 2025-06-06 | Levit Alex C. | Chief Legal Officer, Corp. Sec | Open market purchase | 20,000 | $0.58 |
| 2025-06-06 | Minai-Azary Jennifer Lynn | Chief Financial Officer | Open market purchase | 40,010 | $0.64 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:36 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-31 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-26 | 8-K | 2026-06-24 | View on SEC.gov → |
| 2026-06-15 | 8-K | 2026-06-15 | View on SEC.gov → |
| 2026-05-18 | 8-K | 2026-05-14 | View on SEC.gov → |
Recent news
Headlines about CNTX (Context Therapeutics Inc.). Links open the publisher — we don’t host full articles.
-
New Strong Sell Stocks for October 15th
Yahoo · 2026-10-15 -
New Strong Sell Stocks for October 13th
Yahoo · 2026-10-13 -
Context drops bispecific T-cell engager on cost-cutting initiative
Yahoo Finance · 2026-08-07 -
Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More
Yahoo Finance · 2026-08-07 -
Context Therapeutics GAAP EPS of -$0.15
Seeking Alpha · 2026-08-05 -
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Yahoo Finance · 2026-08-05 -
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance · 2026-07-10 -
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
Yahoo Finance · 2026-07-06
No headlines in this category right now — try “All”.